{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T12:50:04Z","timestamp":1752670204710,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Daewon Pharmaceutical Co., Ltd. Korea"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-90779-6","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:04:45Z","timestamp":1740121485000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of using oral spherical carbon adsorbent in predialysis chronic kidney disease period on cardiovascular outcome after dialysis therapy"],"prefix":"10.1038","volume":"15","author":[{"given":"Takhyeon","family":"Kweon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youn Kyung","family":"Kee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Ho","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieun","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee Jung","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"90779_CR1","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E. & Hsu, C. Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl. J. Med. 351, 1296\u20131305. https:\/\/doi.org\/10.1056\/NEJMoa041031 (2004).","journal-title":"N Engl. J. Med."},{"key":"90779_CR2","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","volume":"108","author":"MJ Sarnak","year":"2003","unstructured":"Sarnak, M. J. et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in Cardiovascular Disease, high blood pressure research, clinical cardiology, and Epidemiology and Prevention. Circulation 108, 2154\u20132169. https:\/\/doi.org\/10.1161\/01.CIR.0000095676.90936.80 (2003).","journal-title":"Circulation"},{"key":"90779_CR3","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1046\/j.1523-1755.2003.00924.x","volume":"63","author":"R Vanholder","year":"2003","unstructured":"Vanholder, R. et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 63, 1934\u20131943. https:\/\/doi.org\/10.1046\/j.1523-1755.2003.00924.x (2003).","journal-title":"Kidney Int."},{"key":"90779_CR4","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1681\/ASN.2011121175","volume":"23","author":"F Duranton","year":"2012","unstructured":"Duranton, F. et al. Normal and pathologic concentrations of uremic toxins. J. Am. Soc. Nephrol. 23, 1258\u20131270. https:\/\/doi.org\/10.1681\/ASN.2011121175 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"90779_CR5","doi-asserted-by":"publisher","unstructured":"Vanholder, R., Pletinck, A., Schepers, E. & Glorieux, G. Biochemical and clinical impact of Organic Uremic Retention solutes: a Comprehensive Update. Toxins (Basel) 10. https:\/\/doi.org\/10.3390\/toxins10010033 (2018).","DOI":"10.3390\/toxins10010033"},{"key":"90779_CR6","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1159\/000064291","volume":"91","author":"N Kobayashi","year":"2002","unstructured":"Kobayashi, N. et al. Effects of oral adsorbent AST-120 (Kremezin) on renal function and glomerular injury in early-stage renal failure of subtotal nephrectomized rats. Nephron 91, 480\u2013485. https:\/\/doi.org\/10.1159\/000064291 (2002).","journal-title":"Nephron"},{"key":"90779_CR7","unstructured":"Niwa, T. et al. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int. Suppl. 62, S23\u201328 (1997)."},{"key":"90779_CR8","first-page":"96","volume":"124","author":"T Niwa","year":"1994","unstructured":"Niwa, T. & Ise, M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J. Lab. Clin. Med. 124, 96\u2013104 (1994).","journal-title":"J. Lab. Clin. Med."},{"key":"90779_CR9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1159\/000187065","volume":"62","author":"Y Yoshida","year":"1992","unstructured":"Yoshida, Y., Sakai, T. & Ise, M. Effects of oral adsorbent in the rat model of chronic renal failure. Nephron 62, 305\u2013314. https:\/\/doi.org\/10.1159\/000187065 (1992).","journal-title":"Nephron"},{"key":"90779_CR10","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/ki.1991.233","volume":"40","author":"M Motojima","year":"1991","unstructured":"Motojima, M. et al. Role for uremic toxin in the progressive loss of intact nephrons in chronic renal failure. Kidney Int. 40, 461\u2013469. https:\/\/doi.org\/10.1038\/ki.1991.233 (1991).","journal-title":"Kidney Int."},{"key":"90779_CR11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1159\/000063324","volume":"92","author":"I Ishikawa","year":"2002","unstructured":"Ishikawa, I. et al. Effect of oral adsorbent (AST-120) on renal function, acquired renal cysts and aortic calcification in rats with adriamycin nephropathy. Nephron 92, 399\u2013406. https:\/\/doi.org\/10.1159\/000063324 (2002).","journal-title":"Nephron"},{"key":"90779_CR12","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1159\/000190236","volume":"76","author":"K Okada","year":"1997","unstructured":"Okada, K., Shibahara, H. & Takahashi, S. Effect of oral adsorbent on the progression of diabetic nephropathy. Nephron 76, 489\u2013490. https:\/\/doi.org\/10.1159\/000190236 (1997).","journal-title":"Nephron"},{"key":"90779_CR13","first-page":"S188","volume":"63","author":"A Owada","year":"1997","unstructured":"Owada, A. et al. Effects of oral adsorbent AST-120 on the progression of chronic renal failure: a randomized controlled study. Kidney Int. Suppl. 63, S188\u2013190 (1997).","journal-title":"Kidney Int. Suppl."},{"key":"90779_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3349\/ymj.2021.62.1.41","volume":"62","author":"YK Kee","year":"2021","unstructured":"Kee, Y. K. et al. Comparison of different types of oral adsorbent therapy in patients with chronic kidney disease: a Multicenter, Randomized, Phase IV Clinical Trial. Yonsei Med. J. 62, 41\u201349. https:\/\/doi.org\/10.3349\/ymj.2021.62.1.41 (2021).","journal-title":"Yonsei Med. J."},{"key":"90779_CR15","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.3346\/jkms.2019.34.e117","volume":"34","author":"YC Hwang","year":"2019","unstructured":"Hwang, Y. C. et al. Predictive factors for efficacy of AST-120 treatment in Diabetic Nephropathy: a prospective Single-Arm, Open-Label, Multi-center Study. J. Korean Med. Sci. 34, e117. https:\/\/doi.org\/10.3346\/jkms.2019.34.e117 (2019).","journal-title":"J. Korean Med. Sci."},{"key":"90779_CR16","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1681\/ASN.2014010042","volume":"26","author":"G Schulman","year":"2015","unstructured":"Schulman, G. et al. Randomized placebo-controlled EPPIC trials of AST-120 in CKD. J. Am. Soc. Nephrol. 26, 1732\u20131746. https:\/\/doi.org\/10.1681\/ASN.2014010042 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"90779_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12882-016-0357-9","volume":"17","author":"G Schulman","year":"2016","unstructured":"Schulman, G. et al. The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials. BMC Nephrol. 17, 141. https:\/\/doi.org\/10.1186\/s12882-016-0357-9 (2016).","journal-title":"BMC Nephrol."},{"key":"90779_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.23876\/j.krcp.2017.36.1.68","volume":"36","author":"RH Cha","year":"2017","unstructured":"Cha, R. H. et al. Sustained uremic toxin control improves renal and cardiovascular outcomes in patients with advanced renal dysfunction: post-hoc analysis of the Kremezin Study against renal disease progression in Korea. Kidney Res. Clin. Pract. 36, 68\u201378. https:\/\/doi.org\/10.23876\/j.krcp.2017.36.1.68 (2017).","journal-title":"Kidney Res. Clin. Pract."},{"key":"90779_CR19","doi-asserted-by":"publisher","first-page":"676345","DOI":"10.3389\/fphar.2021.676345","volume":"12","author":"PY Su","year":"2021","unstructured":"Su, P. Y. et al. Efficacy of AST-120 for patients with chronic kidney disease: a Network Meta-Analysis of Randomized controlled trials. Front. Pharmacol. 12, 676345. https:\/\/doi.org\/10.3389\/fphar.2021.676345 (2021).","journal-title":"Front. Pharmacol."},{"key":"90779_CR20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000453673","volume":"135","author":"J Yamaguchi","year":"2017","unstructured":"Yamaguchi, J., Tanaka, T. & Inagi, R. Effect of AST-120 in chronic kidney Disease Treatment: still a controversy? Nephron 135, 201\u2013206. https:\/\/doi.org\/10.1159\/000453673 (2017).","journal-title":"Nephron"},{"key":"90779_CR21","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s00380-015-0785-7","volume":"31","author":"E Sato","year":"2016","unstructured":"Sato, E. et al. Long-term effects of AST-120 on the progression and prognosis of pre-dialysis chronic kidney disease: a 5-year retrospective study. Heart Vessels 31, 1625\u20131632. https:\/\/doi.org\/10.1007\/s00380-015-0785-7 (2016).","journal-title":"Heart Vessels"},{"key":"90779_CR22","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1159\/000324354","volume":"33","author":"K Nakai","year":"2011","unstructured":"Nakai, K. et al. Effects of AST-120 on left ventricular mass in predialysis patients. Am. J. Nephrol. 33, 218\u2013223. https:\/\/doi.org\/10.1159\/000324354 (2011).","journal-title":"Am. J. Nephrol."},{"key":"90779_CR23","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1080\/08860220802356531","volume":"30","author":"H Ueda","year":"2008","unstructured":"Ueda, H., Shibahara, N., Takagi, S., Inoue, T. & Katsuoka, Y. AST-120 treatment in pre-dialysis period affects the prognosis in patients on hemodialysis. Ren. Fail. 30, 856\u2013860. https:\/\/doi.org\/10.1080\/08860220802356531 (2008).","journal-title":"Ren. Fail."},{"key":"90779_CR24","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3390\/toxins10050202","volume":"10","author":"H Fujii","year":"2018","unstructured":"Fujii, H., Goto, S. & Fukagawa, M. Role of Uremic toxins for kidney, Cardiovascular, and bone dysfunction. Toxins (Basel) 10, 202. https:\/\/doi.org\/10.3390\/toxins10050202 (2018).","journal-title":"Toxins (Basel)"},{"key":"90779_CR25","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1111\/bph.13417","volume":"173","author":"H Fujii","year":"2016","unstructured":"Fujii, H. et al. Anti-oxidative effect of AST-120 on kidney injury after myocardial infarction. Br. J. Pharmacol. 173, 1302\u20131313. https:\/\/doi.org\/10.1111\/bph.13417 (2016).","journal-title":"Br. J. Pharmacol."},{"key":"90779_CR26","doi-asserted-by":"publisher","first-page":"e83687","DOI":"10.1371\/journal.pone.0083687","volume":"8","author":"S Lekawanvijit","year":"2013","unstructured":"Lekawanvijit, S. et al. The uremic toxin adsorbent AST-120 abrogates cardiorenal injury following myocardial infarction. PLoS One 8, e83687. https:\/\/doi.org\/10.1371\/journal.pone.0083687 (2013).","journal-title":"PLoS One"},{"key":"90779_CR27","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1161\/01.ATV.14.5.653","volume":"14","author":"JP Cooke","year":"1994","unstructured":"Cooke, J. P. & Tsao, P. S. Is NO an endogenous antiatherogenic molecule? Arterioscler. Thromb. 14, 653\u2013655 (1994).","journal-title":"Arterioscler. Thromb."},{"key":"90779_CR28","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1161\/01.cir.99.24.3092","volume":"99","author":"A Ito","year":"1999","unstructured":"Ito, A. et al. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 99, 3092\u20133095. https:\/\/doi.org\/10.1161\/01.cir.99.24.3092 (1999).","journal-title":"Circulation"},{"key":"90779_CR29","doi-asserted-by":"publisher","first-page":"e0116468","DOI":"10.1371\/journal.pone.0116468","volume":"10","author":"D Lanza","year":"2015","unstructured":"Lanza, D. et al. Impact of the uremic milieu on the osteogenic potential of mesenchymal stem cells. PLoS One 10, e0116468. https:\/\/doi.org\/10.1371\/journal.pone.0116468 (2015).","journal-title":"PLoS One"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90779-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90779-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90779-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:50:20Z","timestamp":1740163820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90779-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["90779"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-90779-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"26 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6315"}}